Multi-center non-drug-interventional extension study to assess long-term safety and effects on growth in patients who received bosentan or placebo as adjunctive therapy to inhaled nitric oxide for persistent pulmonary hypertension of the newborn in FUTURE 4 (AC-052-391)
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2017
Price : $35 *
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 05 Jun 2016 Status changed from active, no longer recruiting to completed.
- 04 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by UKCRN record.
- 08 Apr 2014 New trial record